CN111556750B - 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途 - Google Patents

线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途 Download PDF

Info

Publication number
CN111556750B
CN111556750B CN201880085315.7A CN201880085315A CN111556750B CN 111556750 B CN111556750 B CN 111556750B CN 201880085315 A CN201880085315 A CN 201880085315A CN 111556750 B CN111556750 B CN 111556750B
Authority
CN
China
Prior art keywords
mitochondrial dysfunction
drug
diseases
mitochondrial
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880085315.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111556750A (zh
Inventor
小坂仁
山形崇伦
神保恵理子
宫内彰彦
阿部高明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Jichi Medical University
Original Assignee
Tohoku University NUC
Jichi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, Jichi Medical University filed Critical Tohoku University NUC
Publication of CN111556750A publication Critical patent/CN111556750A/zh
Application granted granted Critical
Publication of CN111556750B publication Critical patent/CN111556750B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880085315.7A 2017-11-07 2018-11-07 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途 Expired - Fee Related CN111556750B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-214460 2017-11-07
JP2017214460A JP6958860B2 (ja) 2017-11-07 2017-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
PCT/JP2018/041354 WO2019093379A1 (ja) 2017-11-07 2018-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途

Publications (2)

Publication Number Publication Date
CN111556750A CN111556750A (zh) 2020-08-18
CN111556750B true CN111556750B (zh) 2023-05-26

Family

ID=66437831

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880085315.7A Expired - Fee Related CN111556750B (zh) 2017-11-07 2018-11-07 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途

Country Status (5)

Country Link
US (1) US11369615B2 (enExample)
EP (1) EP3708161A4 (enExample)
JP (1) JP6958860B2 (enExample)
CN (1) CN111556750B (enExample)
WO (1) WO2019093379A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7265926B2 (ja) 2019-04-26 2023-04-27 株式会社Ｎｔｔドコモ 通信制御装置および通信制御方法
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023085420A1 (ja) 2021-11-15 2023-05-19 学校法人自治医科大学 フェロトーシス阻害剤及びその用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548986A (zh) * 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
CA2920272A1 (en) * 2015-02-13 2016-08-13 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof to treat and prevent mitochondrial diseases and conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56166116A (en) * 1980-05-26 1981-12-21 Showa Denko Kk Carcinostatic agent
CA2375542A1 (en) * 1999-06-22 2000-12-28 James A. Dykens Compositions and methods for assaying subcellular conditions and processes energy transfer
HU228783B1 (en) 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
ES2699077T3 (es) * 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
JP2012041314A (ja) * 2010-08-22 2012-03-01 Kanazawa Univ 脳腫瘍治療用キット及び脳腫瘍治療方法
EA025033B1 (ru) 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
CA2865316A1 (en) * 2011-04-28 2012-11-01 Gino Cortopassi Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
EP2739285B9 (en) * 2011-08-02 2019-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Selective inhibition of malt1 protease by phenothiazine derivatives
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
CA2939219C (en) * 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
JP6763691B2 (ja) 2016-05-30 2020-09-30 上野製薬株式会社 熱可塑性樹脂組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548986A (zh) * 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
CA2920272A1 (en) * 2015-02-13 2016-08-13 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof to treat and prevent mitochondrial diseases and conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Apomorphine prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart;IGOR KHALIULIN et al.;《Free Radical Biology & Medicine》;20040723;第37卷(第7期);第969-976页 *
IGOR KHALIULIN et al..Apomorphine prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart.《Free Radical Biology & Medicine》.2004,第37卷(第7期),第969-976页. *
线粒体脑肌病伴乳酸酸中毒和卒中样发作综合征;陈春暖等;《临床神经病学杂志》;20111231;第24卷(第4期);第314-317页 *

Also Published As

Publication number Publication date
CN111556750A (zh) 2020-08-18
JP2019085364A (ja) 2019-06-06
US11369615B2 (en) 2022-06-28
JP6958860B2 (ja) 2021-11-02
EP3708161A4 (en) 2021-08-18
WO2019093379A1 (ja) 2019-05-16
EP3708161A1 (en) 2020-09-16
US20200330475A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
US20200062712A1 (en) Aldehyde trapping compounds and uses thereof
CN111556750B (zh) 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
US20200223851A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
JP2010522697A (ja) キナーゼタンパク質結合阻害剤
US11834404B2 (en) Derivatives of sulindac can protect normal cells against oxidative damage
US12398110B2 (en) Second generation inhibitors of mitochondrial permeability transition pore with improved plasma stability
US20200061064A1 (en) Anti-aging compounds
KR20240012533A (ko) 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도
US20130178503A1 (en) Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
KR20180033957A (ko) 칼콘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 미토콘드리아의 산소 소모율 감소에 의해 야기되는 질환의 예방 또는 치료용 약학 조성물
JP7360229B2 (ja) フェロトーシス阻害剤及びその用途
EP3658129A1 (en) Glucose-6-phosphate dehydrogenase (g6pd)-modulating agents and methods of treating g6pd deficiency
US20250235413A1 (en) Modified forms of ambroxol for therapeutic use
WO2013120896A1 (en) Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (pde4)
WO2018204987A1 (en) Carbonic anhydrase inhibitors
WO2024229096A1 (en) Modified forms of ambroxol for therapeutic use
IL322951A (en) Hydroxyalkyl and methoxyalkyl-modified tryptamines
JPWO2009093471A1 (ja) アポトーシス抑制薬
JP2019199438A (ja) プロテオリピドタンパク質１の構造不全の改善剤、及びプロテオリピドタンパク質１の構造不全に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
WO2016084870A1 (ja) アシルアミノフェニル基を有する化合物及びその用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230526

CF01 Termination of patent right due to non-payment of annual fee